Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Novogene CoSHSE:688315 -2.93%84 EBITDA Margin % is 6.97% as of Mar. 2026, which is 61% below its 10-year median of 17.95. GuruFocus rates SHSE:688315 with a GF Score™ of 84/100 and a GF Value™ of ¥15.99 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 940 Biotechnology companies, Novogene Co ranks better than 73.94% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Novogene Co's EBITDA for the
three
months ended in Mar. 2026 was ¥39 Mil. Novogene Co's Revenue for the
three
months ended in Mar. 2026 was ¥556 Mil. Therefore, Novogene Co's EBITDA margin for the quarter that ended in Mar. 2026 was 6.97%.
Novogene Co (SHSE:688315) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Novogene Co EBITDA Margin % Related Terms
Novogene Co EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Novogene Co's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688315 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Novogene Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Novogene Co EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Novogene Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Novogene Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novogene Co (SHSE:688315) has a EBITDA Margin % of 6.97% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Novogene Co and its competitors. This is 61% below median its historical median of 17.95. Over the past decade, Novogene Co's EBITDA Margin % has ranged from 8.58 to 20.45. According to the industry distribution chart, Novogene Co ranks #245 out of 940 companies in the Biotechnology industry, placing it in the top 26.1%.
Is Novogene Co's EBITDA Margin % too high?
Novogene Co's current EBITDA Margin % of 6.97% is 61% below median its 10-year median of 17.95. Over the past 10 years, this metric has ranged from a low of 8.58 to a high of 20.45. Based on the distribution chart, Novogene Co ranks #245 out of 940 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Novogene Co has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Novogene Co's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Novogene Co ranks #245 out of 940 companies for EBITDA Margin %. This puts Novogene Co in the upper half of its industry. Historically, Novogene Co's own EBITDA Margin % has ranged from 8.58 to 20.45 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Novogene Co and its competitors. Novogene Co's current EBITDA Margin % is 6.97%, which is 61% below median its own 10-year median of 17.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novogene Co stock overvalued right now?
Based on GuruFocus' analysis, Novogene Co (SHSE:688315) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥15.99, compared to a current price of ¥11.94 — trading 25.3% below its estimated fair value. The current EBITDA Margin % is 6.97%, which is 61% below median its 10-year median of 17.95. Novogene Co's overall GF Score™ is 84/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Novogene Co (SHSE:688315), the current EBITDA Margin % is 6.97% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Novogene Co (SHSE:688315) Overvalued in 2026?
Based on GuruFocus' analysis, Novogene Co stock appears to be undervalued.
The current stock price of ¥11.94 is trading 25.3% below its estimated GF Value™ of ¥15.99.
GuruFocus considers Novogene Co to be Modestly Undervalued.
Key valuation signals for SHSE:688315:
EBITDA Margin %: 6.97% (61% below median its 10-year median of 17.95)
GF Value™: ¥15.99 vs. price of ¥11.94 (25.3% below fair value)
No single metric tells the full story. See the SHSE:688315 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Novogene Co Ltd is engaged in providing multi-level scientific research and technical services and solutions for life science basic research, medical and clinical application research, and independent development and innovation of genetic testing medical equipment.
84GF Score
Get the complete analysis for SHSE:688315
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688315 has been successfully added to your 
